Buyukbayram, M. E. Et Al. 2024. The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker. Breast Cancer: Targets and Therapy , vol.16 , 329-339.

Buyukbayram, M. E., Hannarici, Z., Duzkopru, Y., TURHAN, A., ÇAĞLAR, A. A., Esdur, P. C., ... BİLİCİ, M.(2024). The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker. Breast Cancer: Targets and Therapy , vol.16, 329-339.

Buyukbayram, Mehmet Et Al. "The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker," Breast Cancer: Targets and Therapy , vol.16, 329-339, 2024

Buyukbayram, Mehmet E. Et Al. "The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker." Breast Cancer: Targets and Therapy , vol.16, pp.329-339, 2024

Buyukbayram, M. E. Et Al. (2024) . "The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker." Breast Cancer: Targets and Therapy , vol.16, pp.329-339.

@article{article, author={Mehmet Emin Buyukbayram Et Al. }, title={The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker}, journal={Breast Cancer: Targets and Therapy}, year=2024, pages={329-339} }